Abonour, RafatRifkin, Robert M.Gasparetto, CristinaToomey, KathleenDurie, Brian G.M.Hardin, James W.Terebelo, Howard R.Jagannath, SundarNarang, MohitAilawadhi, SikanderOmel, James L.Lee, Hans C.Srinivasan, ShankarKitali, AmaniAgarwal, AmitWagner, Lynne2022-08-172022-08-172021-04Abonour R, Rifkin RM, Gasparetto C, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry. Br J Haematol. 2021;193(1):93-100. doi:10.1111/bjh.17131https://hdl.handle.net/1805/29803Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalHealth‐related quality of lifeLenalidomideMultiple myelomaReal‐world evidenceArticle